PRTC vs. INDV, APGE, IRON, BHC, BEAM, ARQT, BHVN, SDGR, EWTX, and JANX
Should you be buying PureTech Health stock or one of its competitors? The main competitors of PureTech Health include Indivior (INDV), Apogee Therapeutics (APGE), Disc Medicine (IRON), Bausch Health Companies (BHC), Beam Therapeutics (BEAM), Arcutis Biotherapeutics (ARQT), Biohaven (BHVN), Schrödinger (SDGR), Edgewise Therapeutics (EWTX), and Janux Therapeutics (JANX). These companies are all part of the "pharmaceutical products" industry.
PureTech Health vs.
PureTech Health (NASDAQ:PRTC) and Indivior (NASDAQ:INDV) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, community ranking, analyst recommendations, valuation, profitability, risk, institutional ownership and media sentiment.
In the previous week, Indivior had 5 more articles in the media than PureTech Health. MarketBeat recorded 7 mentions for Indivior and 2 mentions for PureTech Health. PureTech Health's average media sentiment score of 1.78 beat Indivior's score of 1.35 indicating that PureTech Health is being referred to more favorably in the media.
PureTech Health has a net margin of 0.00% compared to Indivior's net margin of -3.96%. PureTech Health's return on equity of 0.00% beat Indivior's return on equity.
Indivior received 2 more outperform votes than PureTech Health when rated by MarketBeat users. Likewise, 100.00% of users gave Indivior an outperform vote while only 45.00% of users gave PureTech Health an outperform vote.
PureTech Health has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500. Comparatively, Indivior has a beta of 0.66, suggesting that its stock price is 34% less volatile than the S&P 500.
0.0% of PureTech Health shares are held by institutional investors. Comparatively, 60.3% of Indivior shares are held by institutional investors. 5.3% of PureTech Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Indivior has higher revenue and earnings than PureTech Health.
PureTech Health presently has a consensus target price of $45.00, suggesting a potential upside of 140.58%. Indivior has a consensus target price of $15.00, suggesting a potential upside of 9.57%. Given PureTech Health's stronger consensus rating and higher probable upside, research analysts clearly believe PureTech Health is more favorable than Indivior.
Summary
PureTech Health and Indivior tied by winning 8 of the 16 factors compared between the two stocks.
Get PureTech Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRTC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PureTech Health Competitors List
Related Companies and Tools
This page (NASDAQ:PRTC) was last updated on 6/11/2025 by MarketBeat.com Staff
